other material
confidence high
sentiment neutral
materiality 0.12
Harmony Biosciences corrects Zynerba merger agreement filing, removes non-binding disclaimer
Harmony Biosciences Holdings, Inc.
- Filed Amendment No. 1 to 8-K to correct Merger Agreement cover page that erroneously stated it was not binding.
- Corrected agreement is identical to August 14 version except for removal of the disclaimer.
- Merger consideration unchanged: $1.1059 per share cash plus one contingent value right per Zynerba share.
- No financial or operational changes; correction is procedural and does not alter the transaction terms.